PDS Biotechnology (PDSB) Net Equity Issued and Repurchased (2016 - 2025)

PDS Biotechnology (PDSB) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $2.7 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.5 million (changed N/A YoY) and the FY2025 annual result came in at $9.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased improved to $2.7 million in Q4 2025, from $1.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $51.7 million in Q2 2021 to a low of $200000.0 in Q2 2023.
• A 4-year average of $9.0 million and a median of $3.7 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 6.32% in 2023, down 6.32% in 2023.
• Tracing PDSB's Net Equity Issued and Repurchased over 4 years: stood at $51.7 million in 2021, then plunged by 80.94% to $9.9 million in 2022, then climbed by 6.32% to $10.5 million in 2023, then plunged by 74.09% to $2.7 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $2.7 million (Q4 2025), $1.3 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.